Lorlatinib, an investigational drug candidate currently in late-stage clinical development for the treatment of lung cancer may also prove effective for the treatment of the pediatric cancer neuroblastoma. Solving Kids’ Cancer is leading an international effort of like-minded nonprofits to provide nearly $400,000 of collaborative funding for an innovative clinical trial to bring a potentially life-saving therapy to kids.
September is childhood cancer awareness month, and childhood cancer awareness is represented by the color gold. We are encouraging kids to swap out their shoelaces during the month of September and support kids fighting cancer by wearing gold.
Join us and watch as we recap all of the milestones & events Solving Kids’ Cancer experienced during 2016. From our 6th Annual Spring Celebration to SKC appealing NICE’s decision in the UK – none of these accomplishments could have been possible without the help of our supporters. Thank you & Happy New Year!
Runway Heroes is a fun-filled fashion show featuring childhood cancer fighters and survivors ranging in age from 3 to 13 years of age. The runway is presented by Bloomingdale’s at its flagship Manhattan store, and benefits Solving Kids’ Cancer and the Ronan Thompson Foundation, two like-minded nonprofits that collaborate on funding innovative childhood cancer research. In high fashion and chic style, these runway stars shine with a sense of pride and accomplishment as they strut their stuff in trend-setting outfits donated by Bloomingdale’s.
Solving Kids’ Cancer was the first charity to ever go against the UK healthcare system without a pharmaceutical company involved. As a result, the National Institute for Health and Care Excellence (NICE) recently announced that it has upheld SKC’s appeal against the Institute’s decision not to recommend dinutuximab for treating high-risk neuroblastoma.
Solving Kids’ Cancer (SKC) together with Wade’s Army announce their joint financial support of this Phase 1 clinical trial to test the safety and efficacy of various investigational drugs that will leverage precision medicine for children with neuroblastoma. This Next Generation Personalized Neuroblastoma Therapy – also known as NEPENTHE (Greek for “medicine for sorrow”) – is the first precision medicine trial for children that will robustly analyze the genomics of their cancer and use combinations of investigational drugs to target specific mutations in their tumors.
The Andrew McDonough B+ Foundation (The B+ Foundation) and Solving Kids’ Cancer (SKC) presented a check for $208,500 to Dr. Matthias Gromeier and Dr. Eric Thompson at the Preston Robert Tisch Brain Tumor Center at Duke, to co-fund an exciting new immunotherapy trial for children with deadly brain tumors.
A Kids’ Brain Tumor Cure Foundation, Solving Kids’ Cancer, and the Ty Louis Campbell (TLC) Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.
The National Institute for Health and Care Excellence (NICE) heard an appeal led by Solving Kids’ Cancer (SKC) against its recent decision to deny children in the UK treatment that is proven to significantly increase the chance of survival for children diagnosed with an aggressive childhood cancer, neuroblastoma.